

# NON-ALCOHOLIC FATTY LIVER YOUTH WITH OBESITY



Marina Ybarra<sup>1</sup>, Mariana Deboni<sup>1</sup>, Ruth Rocha Franco<sup>1</sup>, Iana Manuelle de Araújo<sup>1</sup>, Instituto da Criar Hospital das Clínicas - FN Marcela Salum D'Alessandro<sup>1</sup>, Louise Cominato<sup>1</sup>, Manoel Carlos Prieto Velhote<sup>1</sup>, Silvia Sucena<sup>1</sup>, Marcia Wang<sup>1</sup>, Durval Damiani<sup>1</sup>, Ricardo Katsuya Toma<sup>1</sup>, Gilda Porta<sup>2,3</sup>

<sup>1</sup>Children's Institute — University of São Paulo, Brazil; <sup>2</sup>Hepatology and Liver Transplantation Unit - Menino Jesus Hospital, Brazil; <sup>3</sup>Hepatology and Liver Transplantation Unit — Syrian Libanese Hospital, Brazil

#### **BACKGROUND**

- Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease seen in the pediatric population
- It occurs in the setting of: insulin resistance and increased adiposity
- NAFLD can be:
  - Non-alcoholic fatty liver (NAFL): bland steatosis
- Non-alcoholic steatohepatitis (NASH): steatosis and lobular inflammation and hepatocellular injury
- Fibrosis: indicate a more severe phenotype even in the absence of NASH
- Liver biopsy should be considered in children who have increased risk of NASH and/or advanced fibrosis (1B)
  - → ↑ liver enzymes (ALT>80 U/L or AST/ALT>1)
  - → splenomegaly
  - $\rightarrow$  T2D
  - panhypopituitarism

#### **OBJECTIVE**

To investigate NAFLD in youth with overweight and obesity

### **METHODS**

- Retrospective analyses
  - Clinical
  - Laboratory
  - Imaging
  - Histological data
- Underwent liver biopsy:
  - during bariatric surgery (n=22)
  - percutaneously (n=15)
- Exclusion criteria: other causes of chronic liver diseases
- Results: NASPGHAN criteria
- Approved by the Institutional Ethic Committee and patient/parental consent was obtained

- Co-morbidities evaluated:
  - 1 Liver enzymes
  - Splenomegaly
  - Hypertension: BP ≥ 130x80mmHg or use of anti-hypertensive drugs
  - Dysglycemia:
    - T2D: 2h-OGTT > 200 mg/dL
    - IGT: 140 < 2h OGTT< 200 mg/dL
    - IR: HOMA-IR ≥ 2.5
  - Dyslipidemia:

TC > 200 mg/dL

non-LDL-C > 135 mg/dL

HDL- C  $< 40 \circlearrowleft$ 

HDL- C < 45 ♀

TG > 130 mg/dL

## **RESULTS**

37 children and adolescents with overweight/obesity (2006-2017)

mean **age**: 15.8 years (7-21)


mean **BMI**: 39.3 kg/m<sup>2</sup>

0% splenomegaly


65% 👌


73% ultrasound with steatosis

100% Waist Circumference > p90



REVERSIBLE









Fat Liver (NAFL)

89%
(33/37)


Non-Alcoholic


Steatohepatitis (NASH)


65%
(24/37)


Non-Alcoholic

O% (0/37)









## CONCLUSION

- NAFLD was highly prevalent among youth with overweight/obesity
- Although NASH was diagnosed in 65%, if we were to use NASPGHAN criteria only 20% would have been recommended liver biopsy
- Since NAFLD can result in progressive fibrosis and lead to end-stage liver disease, other criteria should be considered for the early diagnosis in this population



Fat, metabolism and obesity

Marina Ybarra





